Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

Prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)

Details

Files
Project Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Technology Review
Project Number:
HC0060-000

Implementation Advice
Stakeholder Input Deadline June 8, 2023
Draft Report Posted  July 27, 2023
Stakeholder Feedback Deadline August 3, 2023
Final Report Posted August 30, 2023

Files

Implementation Advice View PDF
Last Updated : August 30, 2023